Day Zero Diagnostics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Boston MA US

Primary Industry

Medical Devices & Equipment

About

Founded in 2016 and based in Massachusetts, US, Day Zero Diagnostics, Inc. develops a whole genome sequencing-based diagnostic that identifies the species and antibiotic resistance profile of a bacterial infection. The company's product includes Blood2Bac, a process for ultrahigh enrichment of bacterial DNA from complex clinical samples and MicrohmDB, a microbial resistance database that serves as a training dataset resource for Keynome, the machine learning algorithm for predicting antibiotic resistance profiles.

Current Investors

Golden Seeds, Sands Capital Ventures, TriVentures

Request a demo to show more

Primary Industry

Medical Devices & Equipment

Sub Industries

Molecular Science, Genetics & Gene Therapy, Diagnostic Equipment, Medical Software

Website

www.dayzerodiagnostics.com

Verticals

Artificial Intelligence, HealthTech, Manufacturing

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.